natgillin/translations-raw huggingface dataset:
The composition for use according to claim 22, wherein the gamma-aminobutyric acid agonist, the baclofen or the R-baclofen is administered in a single daily dose, or in two daily doses, or three daily doses, or four daily doses or five daily doses, or in multiple daily doses. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 22, naznačen time što se agonist Y-aminomaslačne kiseline, baklofen ili R-baklofen primijenjuje u jednoj dozi dnevno, ili u dvije doze dnevno, ili tri doze dnevno, ili četiri doze dnevno, ili pet doze dnevno, ili u više doza dnevno.
• conveying the preform to at least one conditioning station at a rate such that the temperature of the surface of the preform does not decrease more than 5° C.; 
PET posuda iz patentnog zahtjeva 8 gdje je temperatura drugog endotermnog prelaza stakla najmanje 20° C. viša nego temperatura prvog endotermnog prelaza stakla.
The method according to any one of claims 1 to 9, wherein the cell density is maintained at less than 2.5x106 cells per mL during the step of culturing the one or more cells, less than 2.0x106 cells per mL during the step of culturing the one or more cells, or less than 1.5x106 cells per mL during the step of culturing the one or more cells. 
gustoću stanica se održava kod manje od 3,0 x 106 stanica po ml u koraku uzgoja jedne ili više stanica; ili gustoću stanica se održava između 3,0 x 106 stanica po ml i 4,0 x 106 stanica po ml u koraku uzgoja jedne ili više stanica.
The present invention also provides a nucleic acid, encoding a tumor associated peptide of the invention. 
Nukleinska kiselina koja se sastoji od niza koji kodira peptid prema jednom od Zahtjeva 1 do 3.
The process as claimed in claim 1, wherein the temperature used in Step (iv) is −10° C. to −5° C. 
Postupak sukladno patentnom zahtjevu 1, naznačeno time, da je temperatura korištena u Koraku (iv) -10 *C do -5 "€.
A method for production of a coating on a solid substrate comprising the steps of applying a liquid coating composition comprising a polyfunctional resin, a fatty acid or derivative thereof and optionally a curing agent and/or one or more additives, wherein the resin comprises functional groups capable of reacting with carboxyl or acyl groups of the fatty acid or derivative thereof, onto the substrate, and curing the coating by heat activation. 
PATENTNI ZAHTJEVI a Postupak za proizvodnju prevlake na krutoj podlozi koji obuhvaća stupanj nanošenja tekućeg premaza koji sadrži dodataka, naznačen time, da smola sadrži funkcionalne skupine koje mogu reagirati s karboksilnim ili acilnim skupinama masne kiseline ili njezinog derivata, na podlogu i otvrdnjavanje prevlake toplinskom aktivacijom.
The mouse rearranges the human VH gene segments and expresses a reverse chimeric immunoglobulin heavy chain that comprises a human VH domain and a mouse CH. 
(a) teški lanac koji sadržava varijabilnu domenu humanog imunoglobulina i nepromjenjivu regiju imunoglobulina miša i/ili
The pharmaceutical composition of claims 1 to 3, wherein the Ig2 SLIT binding domain comprises amino acid residues 151-237 of SEQ ID NO: 1 or amino acid residues 135-221 of SEQ ID NO:3. 
Farmaceutski pripravak u skladu s patentnim zahtjevima 1 do 3, naznačen time što domena koja se veže na Ig2 SLIT sadrži aminokiselinske ostatke 151-237 iz SEQ ID NO: 1 ili aminokiselinski ostaci 135-221 iz SEQ ID NO:3.
is prepared by the following step A4: reacting a compound of formula (4): with ethylenediamine, in the presence of N-bromosuccinimide, and in a solvent mixture, 
pri čemu je spoj s formulom (4): ostavljen da reagira s etilendiaminom, čime se dobiva spoj formule (5). Postupak prema zahtjevu 17, naznačen time što je korak A4 u prisutnosti N-bromosukcinimida.
means for feeding the filtrate from said primary treatment unit to said secondary treatment unit; 
- > sredstvo za dopremu filtrata iz navedene jedinice za primarnu obradu u navedenu jedinicu za sekundarnu obradu;
The cell culture supernatant of claim 6, wherein the hydrolysate is a plant hydrolysate. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što je hidrolizat biljni hidrolizat ili hidrolizat soje.
The anti-IL-5 antibody for the use as claimed in claim 5, wherein the mean plasma concentration of said antibody is 34.1 ± 12.1 µg/mL to 38.2 ± 9.1 µg/mLand/or wherein the AUC(0-inf) of said antibody is 1110 ± 372 µg×day/mL to 1196 ± 254 µg×day/mL. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 5, naznačeno time što je srednja koncentracija u plazmi navedenog protutijela 34,1 ± 12,1 µg/ml do 38,2 ± 9,1 µg/ml i/ili što je AUC(0-∞) za navedeno protutijelo 1110 ± 372 µg×dan/ml do 1196 ± 254 µg×dan/ml.
combining the compound according to claim 1 with a pharmaceutical excipient to form a pharmaceutical composition; 
(a) kombiniranje spoja u skladu s patentnim zahtjevom 1 s farmaceutskim pomoćnim sredstvom da se dobije farmaceutski pripravak;
PCR primers for cloning mouse heavy VH 
Početnice za PCR za kloniranje mišjeg teškog VH
STEP B: adding water to the mixture prepared in STEP A; wherein the amount of water added is preferably in an amount in the range of from 1.0 to 2.0 molar equivalents; 
KORAK B: dodavanje vode u smjesu pripremljenu u KORAKU A; pri čemu je količina dodane vode poželjno u količini u intervalu od 1.0 do 2.0 molarna ekvivalenta;
A pharmaceutical composition for prevention or treatment of a disease selected from the group consisting of osteoporosis, rickets, hypercalcemia, hypocalcemia, heterotropic calcification, osteosclerosis, Paget's disease, hyperparathyroidism, hypoparathyroidism, and pruritis, comprising as an active ingredient, the antibody against human FGF23 or a functional fragment thereof as described in any one of claims 1-9. A hybridoma C10 (Accession No. FERM Bop-10772). 
Farmaceutski sastav za uporabu u metodi sprječavanja ili liječenja bolesti odabrane iz grupe koja se sastoji od osteoporoze, rahitisa, hiperkalcemije, hipokalcemije, heterotrofne kalcifikacije, osteoskleroze, Pagetove bolesti, hiperparatireoidizma, hipoparatireoidizma i pruritusa, navedeni sastav kao aktivni sastojak sadrži protutijelo na ljudski FGF23 ili funkcionalni fragment navedenog protutijela iz bilo kojeg od patentnih zahtjeva 1-5.
is selected from phenyl substituted with 0-2 R7, and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7 wherein the heteroaryl system is selected from quinazolinyl, triazinyl, pyrimidinyl, picolinyl, isonicotinyl, furanyl, indolyl, pyridinyl, pyrazolyl, pyrazinyl, thiazolyl, thiophenyl, and isoxazolyl. 
se izabire između fenila supstituiranog s 0-2 R7, i 5-10-eročlani heteroarilni sustav koji sadrži 1-4 heteroatoma izabrana između N, O, i S, supstituiran s 0-3 R7 gdje se heteroarilni sustav izabire između kinazolinil, triazinil, pirimidinil, pikolinil, izonikotinil, furanil, indolil, piridinil, pirazolil, pirazinil, tiazolil, tiofenil, i izoksazolil.
The hybrid filament is preferably produced using the so-called friction spinning method with which the fibres can be bonded with the core. 
Poželjno je da sc hibridna nit proizvodi na takav način da sc koristi tako zvani postupak frikcijskog predenja pomoću kojega mogu vlakna biti spojena s jezgrom.
A composition for use according to claim 9 in a method comprising: 
Pripravak naznačen time da je za uporabu prema zahtjevu 8 u postupku koji sadrži:
A fixed dose combination of claim 1 or 2 wherein the benazepril pellets of the benazepril layer are coated with a protective layer consisting of a butyl methacrylate-2-dimethylaminoethyl)methacrylate-methylmethacrylate copolymer (1:2:1). 
Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 1 ili 2, naznačena time što pelete s benazeprilom u sloju s benazeprilom su obložene zaštitnim slojem, koji se sastoji od butil-metakrilat–2-dimetilaminoetil-metakrilat–metil-metakrilatnog kopolimera (1:2:1).
All culture flasks and/or tubes used in the study were labeled numerically. 
Sve bočice i/ili epruvete sa kulturom koje su korištene u ovoj studiji obilježene su numerički.
Geometrical calculations and illustrations were performed with PLATON. 
Geometrijski izračuni i ilustracije izvedeni su s PLATON-om.
Examples of compounds of the invention include: 
Datum podnošenja europske prijave patenta:
said packaging material (1, 11) is a box (1) or a paper present in the packaging of a pharmaceutical product 
(d) navedeni pakirni materijal (1, 11) je kutija (1) ili je papir prisutan u pakiranju za farmaceutski proizvod;
represents the side chain of an amino acid residue Ser or Thr; 
R, predstavlja pobočni lanac aminokiselinskog ostatka Ser i Thr;
Subject matter of this invention is a method for the production of (R)-stereoisomers of the esters expressed by the general formula 1.1, which consists in reaction between (R)-stereoisomers of the acids expressed by the formula 1.2 and R4OH alcohol and thionyl chloride (FIG. 
Metoda za proizvodnju estera koji su prikazani općom formulom 1.1, kao što je definirano u patentnom zahtjevu 2, koji se sastoji u reakciji između kiselina koje su prikazane formulom 1.2, kao što je definirano u patentnom zahtjevu 2, i alkohola i tionil klorida.
A developer supply container according to any one of Claims 1 - 6, wherein said drive converting portion (2d, 3b) converts the rotational force so that said pump portion (2b) reciprocates a plurality of times per one full rotation of said feeding portion (2c). 
Spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 - 6, pri čemu navedeni dio za pretvaranje pogona (2d, 3b) pretvara rotacijsku silu tako da navedeni dio za ubrizgavanje (2b) reciprocira više puta tijekom jedne pune rotacije opskrbnog dijela (2c).
The phases were separated, and the aqueous phase was extracted with ethyl acetate (400 mL). 
Faze su separirane i vodena faza je ekstrahirana etil acetatom (400 mL).
an anti-refill dispensing fitment (14, 114, 214, 414, 614) positioned at least partially in the interior passage of the neck of the container, and including at least one ceramic or glass component (34, 134, 234, 434, 534, 136, 436, 636); and 
114, 214. 414. 614). koji se u najmanju ruku dijelom nalazi u unutarnjem prolazu grla spremnika, te uključuje najmanje jednu keramičku ili staklenu komponentu (34, 134, 234.
Accordingly, the pieces of wood being,glued in the process according to the invention, particularly have a relative wood humidity at and above the fiber saturation point. 
U skladu s tim, komadi od drva koji se lijepe u postupku koji je u skladu s ovim izumom, naročito imaju relativnu vlažnost drva kod točke zasićenja vlakana ili iznad te točke.
The expression vector according to claim 7, comprising a nucleotide sequence depicted in SEQ ID NO 90, or its conservative sequence variant. 
ID NO: 89, ili inačica njegovog nepromjenjivog slijeda, ili slijed nukleinskih kiselina opisan u SEQ ID NO: 90, ili inačica njegovog nepromjenjivog slijeda.
The isolated polynucleotide according to claim 5 encoding a polypeptide sequence selected from the group consisting of: SEQ ID NO:84, SEQ ID NO:86, and SEQ ID NO:88; or comprising a sequence selected from the group consisting of: SEQ ID NO:83, SEQ ID NO:85, and SEQ ID NO:87. 
Izolirani polinukleotid sukladno Zahtjevu 5 koji kodira niz polipeptida odabran iz grupe koja sadrži: SEQ ID BR:84, SEQ ID BR:86, i SEQ ID BR:85; ili sadrži niz odabran iz grupe koja se sastoji od SEQ ID BR:83, SEQ ID
A method according to any of the preceding claims, characterised in that individual straight or curved plate-like structures in the form of double-wall structures are produced, in particular a straight plate is produced which is bent so that it exhibits a curved shape, which is rendered permanent. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se proizvode pojedinačne ravne ili zakrivljene pločaste strukture u obliku struktura s dvostrukom stijenkom, pri čemu se osobito proizvodi ravna ploča koja se iskrivi tako da pokazuje zakrivljeni oblik koji se učini trajnim.
Briefly, recombinant CYP2D6 or CYP3A4 is incubated with marker substrate and NADPH generating system (consisting of 1 mM NADP+, 46 mM glucose-6-phosphate and 3 units/mL glucose-6-phosphate dehydrogenase)at 37° C., in the absence or presence of 0.03, 0.09, 0.27, 0.82, 2.5, 7.4, 22, 67 and 200 uM of a sample GnRH antagonist. 
Ukratko, rekombinantni CYP2D6 ili CYP3A4 inkubiran je sa supstratom-biljegom 1 sustavom za proizvodnju NADPH (kojeg čine 1 mM NADP"", 46 mM glukoza-6-fosfat i 3 i.j./ml glukoza-6-fosfat-dehidrogenaze) na 37 "C, u odsutnosti ili prisutnosti 0,03, 0,09, 0,27, 0,82, 2,5, 7,4, 22, 67, te 200 uM uzorka antagonista GnRH.
Therefore there is also achieved a direct stimulating effect on the regeneration of the nucleoside-diphosphate into the nucleoside-triphosphate, which in turn influences the synthesis rate of the complete system DNK-RNK. 
Zbog toga je postignuto također i neposredno djelovanje na poboljšanje regeneracije nukleozid-di-fosfata u nukleozid-tri-fostat, a to utječe na brzinu sinteze cjelokupnog sistema DNK-RNK.
A method for the treatment of an airway disease selected from the group consisting of pulmonary fibrosis, emphysema, chronic bronchitis, asthma, fibrosis, pneumonia, cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchitis rhinitis, and respiratory distress syndrome, the method comprising administering a therapeutic effective amount of the compound of claim 1 to a subject in need thereof. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili pripravak u skladu s patentnim zahtjevom $, za uporabu u prevenciji i/ili liječenju bolesti dišnih puteva izabranih iz skupine koja se sastoji od plućne fibroze, emfizema, kroničnog bronhitisa, astme, fibroze, upale pluća, cistične fibroze, kronične opstruktivne plućne bolesti (COPD), bronhitisa, rinitisa i sindrom respiratornog distresa; poželjno astme ili COPD.
If the dosage form according to the invention comprises a stimulant as active ingredient, the antagonist is preferably a neuroleptic, preferably at least one compound selected from the group consisting of haloperidol, promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, chlorpromazine, chlorprothixine, zuclopentixol, flupentixol, prothipendyl, zotepine, benperidol, pipamperone, melperone and bromperidol. 
Ako oblik davanja prema izumu ima neki stimulans kao djelatnu tvar, antagonist je prvenstveno neuroleptik, prvenstveno spoj izabran iz skupine koju čine Haloperidol, Promethacin, Fluophenazin, Perphenazin, Levomepromazin, Thioridazin, Perazin, Chlorpromazin, Chlorprothixin, Zuclopentixol, Flupentixol, Prothipendyl, Zotepin, Benperidol, Pipamperon, Melperon i Bromperidol.
As described in more detail hereinafter, the compounds of formula I are structural analogs of folic acid and have been found to possess activity as inhibitors of those enzymes that are dependent upon folic acid or folic acid derivatives (folates), such as dihydrofolate reductase (DHFR), at levels comparable to that of methotrexate in vitro. 
Kao što je nadalje opisano u više detalja, spojevi formule I su strukturalni analozi folne kiseline i pronađeno je da imaju aktivnost kao inhibitori onih enzima koji su ovisni o folnoj kiselini ili derivatima folne kiseline (folatima), kao dihidrofolat reduktaza (DHFR), pri nivoima usporedivim s onim metotreksata in vitro.
The compactin sample (30 g) was suspended in methanol (5 times by volume) and heated to reflux. 
Uzorak kompaktina (30 g) je suspendiran u metanolu (u 5 puta većem volumenu) i zagrijan do refluksa.
A use of the compound of claim 1, or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease, such as infections, cancers, diabetes and any other diseases which have been found to be treatable and/or preventable by tetracycline compounds. 
HR P20180444 T1 Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time što je namijenjen upotrebi u liječenju i/ili profilaksi infekcija, raka i dijabetesa.
The bispecific antibody of claim 1, wherein said bispecific antibody comprises a human constant region and human variable domains. 
Protutijelo ili bispecifično protutijelo sukladno patentnim zahtjevima 1-8, koje sadrži humanu konstantnu regiju i humane varijabilne domene.
The method of claim 1, wherein the administering is effective to reduce a level of an additional cytokine that comprises IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, IFN-Y, IL-10, IL-6, or TNFa, in the subject relative to the level of the additional cytokine in the subject before the administering of the pharmaceutical composition to subject. The method of claim 1, wherein the subject has a condition that comprises uveitis; multiple sclerosis; neuromyelitis optica; psoriasis; systemic lupus erythematosus; celiac disease; an asthma; allergic asthma; neutrophilic asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; or allograft rejection. 
Sastav prema zahtjevu 1, pri čemu je sastav za upotrebu u postupku liječenja ili prevencije bolesti ili stanja koje je izabrano iz grupe koja obuhvaća astmu, kao što je alergijska astma ili neutrofilna astma; artritis, kao što je reumatoidni artritis, osteoartritis, psorijazni artritis, ili juvenilni idiopatski artritis; multipla skleroza; optički neuromijelitis (Devicova bolest); ankilozantni spondilitis; spondiloartritis; psorijaza; sistemski eritemski lupus; upalna bolest crijeva, kao što je Crohnova bolest ili ulcerozni kolitis; celijakija; kronična opstruktivna bolest pluća (COPD); uveitis; skleritis; vaskulitis; Behcetovu bolest; ateroskleroza; atopijski dermatitis; emfizem; periodontitis ili parodontoza; alergijski rinitis; i odbacivanje alografta.
The title compound (m=100g) was obtained in a 95 % yield. 
Spoj iz naslova (m = 100 g) dobije se s prinosom od 95 %.
A dietary chocolate composition according to any of the preceding claims, comprising the followings only: erythrol at 8-24% by weight, 
Pripravak za dijetnu čokoladu prema bilo kojem od prethodnih zahtjeva, naznačen time što sadrži isključivo slijedeće sastojke:
desmopressin acetate) of 50 µg, wherein the dose is measured as the free base of desmopressin, for administration prior to bedtime. 
dezmopresin acetat) od 50 µg, naznačen time da se doza mjeri kao slobodna baza dezmopresina, za administraciju prije počinka.
The compound of Formula (I) or the pharmaceutically acceptable salt thereof of claim 1, wherein R1 is a hydrogen atom, and R2 is a hydrogen atom; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol iz patentnog zahtjeva 1, gdje R' je atom vodika, i R* je atom vodika; ravna ili razgranata C;-Cg alkil grupa; ravna ili razgranata Cj-Cs alkoksi grupa; ili ravna ili razgranata Ci-C3 tioalkil grupa.
The host cell according to claim 24, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
CDRH1 sekvencu amino kiseline SEK ID BR: 5;CDRH2 sekvencu amino kiseline SEK ID BR: 20; iCDRH3 sekvencu amino kiseline SEK ID BR: 44 pri čemu je, opcionalno, spomenuta stanica domaćina najmanje jedna izabrana od COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, HepG2, 653, SP2/0, 293, HeLa, mijeloma, ili stanica limfoma, ili bilo kojeg njihovog derivata, imortalizirane ili transformirane stanice.
On the days of testing, each animal was subjected to one trial under the conditions described above. 
Na dan ispitivanja, svaka je životinja podvrgnuta ispitu uz gore navedene uvjete.
4,613,610, indene analogs of mevalonolactone derivatives, as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl)pyran-2-ones and derivatives thereof, as disclosed in U.S. Patent No. 
4,613,610, analozi indena drivata mevalonolaktona, kao što je navedeno u PCT prijavi WO 86/03488, 6-[2-(supstituirani-pirol-1-11)-alkil)piran-2-oni 1 njihovi derivati, kao što je navedeno u U.S. Patentu br.
The loading velocity of the crude material on the column can effect the capture performance of the column, for example, fast loading is more convenient for operation, while slow loading may lead to increase in yield. 
Brzina nanošenja sirovog materijala na kolonu može imati utjecaj na performanse hvatanja kolone, ne primjer, brzno nanošenje je prikladnije za radm dok polaganije nanošenje može dovesti do povećanja prinosa.
The isolated nucleic acid of claim 13, wherein the nucleic acid further encodes a ligand which specifically binds to an antigen or receptor on a cell surface, wherein the ligand is fused directly or through a peptide linker to the PE. 
Izolirana nukleinska kiselina iz zahtjeva 12, nadalje naznačena time da ta nukleinska kiselina kodira citokin, antitijelo ili fragment antitijela koji se specifično veže na neki antigen ili receptor na spomenutoj površini stanice, koji se citotokin, antitijelo ili fragment antitijela fuzionira na spomenuti mutirani PE bilo direktno ili preko neke peptidne veze.
Preferably, the elastase recognition sequence is a type I pancreatic elastase recognition sequence. 
(a) sekvenca za prepoznavanje elastaze ima prolinski ostatak lociran na poziciji P2;
The assembly according to claim 1, wherein said opening in said hollow voice prosthesis tubing (20) is an aperture (22). 
Sklop u skladu s patentnim zahtjevom 1, naznačen time što navedeni otvor u navedenoj cijevi za govornu protezu (20) je otvor (22).
Layer (16) pertains to a scattered particle layer that is fixed to the underlying layer (14) with a resin-based sealing layer (18). 
Sloj (16) je povezan sa slojem rasutih čestica koji je pričvršćen na osnovni sloj (14) s brtvenim slojem na temelju smole (18).
A method of treating a subject suffering from or diagnosed with a sleep disorder selected from the group consisting of sleep-wake transition disorders, insomnia, restless legs syndrome, jet-lag, disturbed sleep, and sleep disorders secondary to neurological disorders, comprising administering to a subject in need of such treatment an effective amount of a compound selected from the group consisting of: 
Barem jedan kemijski entitet i barem jedna farmaceutski prihvatljiva pomoćna tvar za upotrebu prema zahtjevu 7, gdje je spomenuta bolest, poremećaj ili medicinsko stanje poremećaj ciklusa budnosti 1 sna, insomnije, sindroma nemirnih nogu, "jet lag", smetnje pri spavanju i poremećaj spavanja sekundaran neurološkom poremećaju.
Topical vaginal compositions in gel form comprising a colostrum fraction, wherein said colostrum fraction is enriched with immunoglobulins, growth factors, chemotactic factors and antimicrobial/antiviral factors, and wherein said colostrum fraction is partly non-encapsulated and partly encapsulated in mucoadhesive microbeads. 
HR P20170663 T1 HR P20170663 T1 PATENTNI ZAHTJEVI 1. - Topikalni vaginalni pripravci u obliku gela koji sadržavaju frakciju kolostruma obogaćenu imunoglobulinima, faktorima rasta, kemotaktičnim faktorima i antimikrobnim/antivirusnim faktorima, dijelom u slobodnom obliku te dijelom kapsulirano u mukoadhezivnim mikrozrncima.
A compound according to claim 23 for use in treating pain. 
Spoj prema zahtjevu 23 naznačen time da je za uporabu za liječenje boli.
The more hydrophobic the molecule, the less salt needed to promote binding. 
Å to je molekula hidrofobnija manje je soli potrebno za pospješivanje vezanja.
There is a significant difference between the groups at 10 and 20 minutes (Kruskal-Wallis ANOVA, 0 min: p=0.9135; 10 min: p=0.0004; 20 min: p=0.0024). 
Postoji značajna razlika između skupima od 10 i 20 minuta (Kruskal-Wallis ANOVA, 0 min: p = 0,9135; 10 min: p = 0,0004; 20 min: p = 0,0024).
The method of claim 3, wherein the Cas9 protein, the CRISPR RNA, and the tracrRNA are introduced as a protein-RNA complex. 
Postupak sukladno patentnom zahtjevu 3, naznačen time da Cas9 protein, CRISPR RNA, i trarRNA su predstavljen kao protein-RNA kompleks.